



Saskatchewan Immunization Manual Amendments March 2013

Instruction: Please remove and discard the corresponding pages in each chapter section and insert the amended pages as noted below in each corresponding chapter section dated **March 2013**

Chapter 7 Immunization of Special Populations

- TOC (dated May 2012)
 - Hyposplenism added to title of section 1.5.3.
- p.6 (dated May 2012) Section 1.5.1 Chronic Kidney Disease
 - New bullet added to vaccine table: “As of April 1, 2013: 1 dose for Pneu-C-13 naïve children aged 60 months up to and including 17 years of age.”.
- p.7 (dated May 2012) Section 1.5.2 Chronic Kidney Disease
 - New bullet added to vaccine table: “As of April 1, 2013: 1 dose for Pneu-C-13 naïve children aged 60 months up to and including 17 years of age.”.
- p.8 (dated April 2012) Section 1.5.3 Anatomic or Functional Asplenia
 - New section title: Anatomic or Functional Asplenia, or Hyposplenism
 - Essential thrombocytopenia removed as a condition noted in 1st paragraph as a cause of asplenia.
- p.9 (dated May 2012) Section 1.5.3A vaccines for section 1.5.3
 - New bullet added to vaccine table: “As of April 1, 2013: 1 dose for Pneu-C-13 naïve children aged 60 months up to and including 17 years of age.”.
 - Updated Men-C-ACYW-135 vaccine recommendations for this high risk group:
 - “2 doses given not less than 4 weeks apart for those 2 years and older (8 weeks apart is ideal).
 - Revaccination:
 - If vaccinated at 6 years of age or younger, give a booster dose 3-5 years after the last dose, and then give a booster dose every 5 years thereafter.
 - If vaccinated at 7 years of age and older, give a booster dose not less than 5 years after the last dose, and then give a booster dose every 5 years thereafter”.
- p. 12 (dated April 2012) Section 1.5.4A Recommended Vaccine and Immune Globulins for those with illness that progressively weakens the immune system.
 - New bullet added to vaccine table: “As of April 1, 2013: 1 dose for Pneu-C-13 naïve children aged 60 months up to and including 17 years of age.”.
 - Updated HB vaccine dosages for HIV+ individuals:
 - 40µg dose for adults 18 years of age and older.
 - Double dose for children up to and including 17 years of age.
- p. 13 (dated April 2012) Section 1.5.5 Congenital Immunodeficiency States
 - New bullet added to vaccine table: “As of April 1, 2013: 1 dose for Pneu-C-13 naïve children aged 60 months up to and including 17 years of age.”.
 - Rotavirus vaccine added as contraindication.
- p.15 (dated April 2012) Section 1.5.6A Vaccines for those on immunosuppressive therapy
 - New bullet added to vaccine table: “As of April 1, 2013: 1 dose for Pneu-C-13 naïve children aged 60 months up to and including 17 years of age.”.



- p.16 (Dated May 2012) Section 1.5.7 Malignant Neoplasm
 - New bullet added to vaccine table: “As of April 1, 2013: 1 dose for Pneu-C-13 naïve children aged 60 months up to and including 17 years of age.”.
- P.24 (dated November 2012) Section 2.4
 - **Varicella and MMRV removed from table 2.4A.**
- p.25 (dated April 2012) Sections 2.5 and 2.6
 - New bullet added to both vaccine tables: “As of April 1, 2013: 1 dose for Pneu-C-13 naïve children aged 60 months up to and including 17 years of age.”.
- p.26 (dated April 2012) Section 2.7 Cochlear Implant
 - New bullet added to vaccine table: “As of April 1, 2013: 1 dose for Pneu-C-13 naïve children aged 60 months up to and including 17 years of age.”.
- p.27 (dated April 2012) Sections 2.8 and 2.9
 - New bullet added to both vaccine tables: “As of April 1, 2013: 1 dose for Pneu-C-13 naïve children aged 60 months up to and including 17 years of age.”.
- p.28 (dated May 2012) Section 2.10 Individuals with Neurological Disorders
 - New bullet added to vaccine table: “As of April 1, 2013: 1 dose for Pneu-C-13 naïve children aged 60 months up to and including 17 years of age.”.
- P.36 (dated May 2012)
 - **3 new references added.**
- pp. 37 & 38 (dated August 2012 & June 2012 respectively) Appendix 7.1 Publicly Funded Vaccines for Selected Special Populations
 - **New column added for rotavirus vaccine.**
 - **Bleeding disorders – Varicella dot removed along with statement, “child on anti-coagulant therapy.**
 - **Congenital immunodeficiency – Rotavirus added as contraindication.**
 - **Individuals living in facilities – new footnote #12 - Pneu-C-13 for Pneu-C-13 naïve children 60 month-17 years.**
 - **HIV – new foot note #13 - 40µg for those ≥ 18 years; double dose for those birth up to and including 17 years of age.**
 - **Footnote #11 – Essential thrombocytopenia removed; ‘asplenia’ added in before hyposplenia.**
- p. 43 Appendix 7.6 (dated June 2012) Immunization Schedule for Adult Post-Hematopoietic Stem Cell Transplant Recipients
 - **Schedule revised as requested by the Saskatchewan Cancer Agency.**
 - **The SCA endorses that this schedule is to be strictly followed by healthcare providers at the determined intervals. When questions or concerns arise that are related to the SCA’s HSCT immunization schedule, please direct them to SCA or the regional Medical Health Officer.**

Chapter 8 – Administration of Biological products

- TOC 1st page (dated June 2012) table title updates
 - **TABLE 1: VACCINE INTRAMUSCULAR INJECTION SITE, NEEDLE LENGTH AND TOTAL SITE VOLUME PER AGE GROUP**
 - **TABLE 2: IMMUNE GLOBULIN PREPARATION INJECTION SITE, NEEDLE LENGTH AND TOTAL SITE VOLUME PER AGE GROUP**



- p.10 (dated June 2012)
 - Table 1 revised.
 - New table 2 as noted in TOC.

Chapter 10 – Biological Products

- TOC 2nd page (dated May 2012)
 - NIMENRIX™ added as new Men-C-ACYW-135 vaccine from GSK
- TOC 3rd page (dated May 2012)
 - Immune globulin sites table renamed as Immune Globulin Preparation Injection Site, Needle Length and Total Site Volume per Age Group
- HA Eligibility (dated November 2012)
 - Update:
 - Sexual partners and household contacts of individuals who use illicit drugs.
- HB Eligibility (dated November 2012)
 - Updates:
 - Healthcare workers and healthcare students (refer to SIM chapter 7 for definition).
 - Sexual partners and household contacts of individuals who use illicit drugs.
- New vaccine added - NIMENRIX™ added as new Men-C-ACYW-135 vaccine from GSK
- PRIORIX-TETRA (dated August 2012)
 - New product monograph.
 - Expected reaction rates quantified.
 - Adverse event section verbatim from new product monograph re: incidence of fever with 1st vaccine dose.
- p. 2 of 2 Prevnar 13 (dated April 2012)
 - New section C added - (As of April 1, 2013) Medically High-Risk Children Aged 60 Months - 17 Years Who Are at Risk of Invasive Pneumococcal Disease as per Ministry of Health memo dated March 18, 2013.
- Immune Globulin Preparation Injection Site, Needle Length and Total Site Volume per Age Group (dated June 2012)
 - Table revised and updated.